Astrazeneca PLC (AZN): Price and Financial Metrics
Astrazeneca PLC (AZN)
Today's Latest Price: $52.61 USD
Updated Nov 27 1:00pm
Add AZN to WatchlistSign Up
POWR Components:
Trade Grade Buy & Hold Grade Peer Grade Industry Rank
Industry Rank:
Ranked of 240 in Medical - Pharmaceuticals
See all "A" rated Strong Buy stocks
AZN Stock Summary
- With a market capitalization of $138,048,640,000, Astrazeneca Plc has a greater market value than 98.59% of US stocks.
- The price/operating cash flow metric for Astrazeneca Plc is higher than 86.63% of stocks in our set with a positive cash flow.
- The volatility of Astrazeneca Plc's share price is greater than that of merely 10.3% US stocks with at least 200 days of trading history.
- Stocks with similar financial metrics, market capitalization, and price volatility to Astrazeneca Plc are AMGN, LLY, SAP, SNY, and TXN.
- AZN's SEC filings can be seen here. And to visit Astrazeneca Plc's official web site, go to www.astrazeneca.com.
AZN Stock Price Chart Interactive Chart >
AZN Price/Volume Stats
| Current price | $52.61 | 52-week high | $64.94 |
| Prev. close | $52.60 | 52-week low | $36.15 |
| Day low | $51.44 | Volume | 14,783,100 |
| Day high | $52.77 | Avg. volume | 5,237,630 |
| 50-day MA | $54.04 | Dividend yield | 1.67% |
| 200-day MA | $52.20 | Market Cap | 138.08B |
Astrazeneca PLC (AZN) Company Bio
AstraZeneca plc engages in the discovery, development, and commercialization of prescription medicines for the treatment of cardiovascular, metabolic, respiratory, inflammation, autoimmune, oncology, infection, and neuroscience diseases worldwide. The company was founded in 1992 and is based in London, the United Kingdom.
AZN Price Forecast Based on DCF Valuation
| Current Price | DCF Fair Value Target: | Forecasted Gain: |
| $52.61 | $14.82 | -73% |
Below please find a table outlining a discounted cash flow forecast for AZN, in which we model out valuation assuming a variety of terminal growth rates. To summarize, we found that Astrazeneca Plc ranked in the 20th percentile in terms of potential gain offered. We should note, though, that the most conservative analysis suggests this stock will yield negative results -- and thus may be a potential short opportunity. The most interesting components of our discounted cash flow analysis for Astrazeneca Plc ended up being:
- Its compound free cash flow growth rate, as measured over the past 5.75 years, is -0.09% -- higher than only 14.77% of stocks in our DCF forecasting set.
- As a business, AZN is generating more cash flow than 89.13% of positive cash flow stocks in the Healthcare.
- Astrazeneca Plc's weighted average cost of capital (WACC) is 8%; for context, that number is higher than merely 16.49% of tickers in our DCF set.
| Terminal Growth Rate in Free Cash Flow | Return Relative to Current Share Price |
| 0% | -74% |
| 1% | -73% |
| 2% | -73% |
| 3% | -73% |
| 4% | -73% |
| 5% | -72% |
GMED, NRC, BAX, CNC, and MTD can be thought of as valuation peers to AZN, in the sense that they are in the Healthcare sector and have a similar price forecast based on DCF valuation.
Loading social stream, please wait...